M
Mark D. Johnson
Researcher at University of Massachusetts Medical School
Publications - 301
Citations - 18425
Mark D. Johnson is an academic researcher from University of Massachusetts Medical School. The author has contributed to research in topics: Medicine & Gene. The author has an hindex of 60, co-authored 289 publications receiving 16103 citations. Previous affiliations of Mark D. Johnson include National Institutes of Health & Georgetown University Medical Center.
Papers
More filters
Journal ArticleDOI
Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma
Ayal A. Aizer,Nils D. Arvold,Paul J. Catalano,Elizabeth B. Claus,Alexandra J. Golby,Mark D. Johnson,Ossama Al-Mefty,Patrick Y. Wen,David A. Reardon,Eudocia Q. Lee,Lakshmi Nayak,Mikael L. Rinne,Rameen Beroukhim,Stephanie E. Weiss,Shakti Ramkissoon,Malak Abedalthagafi,Sandro Santagata,Ian F. Dunn,Brian M. Alexander +18 more
TL;DR: Patients who have had a gross total resection of an atypical meningioma should be considered for adjuvant radiation therapy given the improvement in local control, according to the results.
Journal ArticleDOI
Epidural fentanyl for postcesarean delivery pain management.
Journal ArticleDOI
Effect of diluent volume on analgesia produced by epidural fentanyl.
TL;DR: To determine the most effective diluent volume, a double-blind, randomized study was undertaken with varying volumes of normal saIine solution to dilute a single 50 pg dose of epidural fentanyl.
Journal ArticleDOI
Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa.
R.B. Dowling,Charlotte F. J. Rayner,Andrew Rutman,Alan D. Jackson,K. Kanthakumar,Ann Dewar,Graham W. Taylor,Peter J. Cole,Mark D. Johnson,Robert Wilson +9 more
TL;DR: Salmeterol reduces P. aeruginosa-induced damage to both organ culture and nasal epithelium and is inhibited by the beta2-adrenoceptor antagonist propranolol.
Journal ArticleDOI
Belonging to a network—microRNAs, extracellular vesicles, and the glioblastoma microenvironment
TL;DR: Establishing how microRNAs are involved in the regulation of oncogenic signaling networks between tumor cells and stroma is likely to add a needed additional layer of complexity to the tumor network, consisting of intercellular communication.